The deadline is quickly approaching on an Army sponsored Request for Proposals (RFP) to develop nerve agent prophylactics.
The overall goal of the project is to select, develop, and manufacture an FDA-approved drug to increase survival and decrease incapacitation such that forces can maintain operational effectiveness within a contaminated area following nerve agent exposure, irrespective of nerve agent type.
The project, managed by U.S. Army Contracting Command Aberdeen Proving Grounds (ACC-APG) Natick Division, seeks to deliver a countermeasure which is safe, quick acting, free from performance-decrementing side effects, compatible with current military CBRN countermeasures, and usable in contemporary operational environments.
The proposed schedule calling for actual delivery of the Bioscavenger (BSCAV)/Nerve Agent Prophylactic is anticipated within 6 years after contract award, but all proposed delivery schedules will be evaluated.
Full details are under Solicitation Number W911QY-12-R-0014. The current response deadline is April 16, 2012.
